Summary
Biogen Idec Inc. (formerly IDEC Pharmaceuticals Corporation) announced the successful completion of its merger with Biogen, Inc. on November 12, 2003. The company has officially changed its name to Biogen Idec Inc. following the merger. Under the terms of the merger, Biogen, Inc. shares were converted into the right to receive 1.15 shares of the Registrant's common stock. This transaction marks a significant strategic move for the combined entity, creating a larger biotechnology company with potentially enhanced capabilities and product portfolios. Investors should note that Biogen, Inc.'s common stock has been delisted from the Nasdaq National Market following the merger, while the combined company's stock now trades under the ticker symbol 'BIIB' on the Nasdaq National Market.
Key Highlights
- 1Completion of the merger between IDEC Pharmaceuticals Corporation and Biogen, Inc. on November 12, 2003.
- 2Registrant's name change to Biogen Idec Inc. effective November 12, 2003.
- 3Biogen, Inc. shareholders received 1.15 shares of Registrant's common stock for each share of Biogen, Inc. common stock owned.
- 4Biogen, Inc. common stock has been delisted from the Nasdaq National Market.
- 5The combined company's common stock now trades under the ticker symbol 'BIIB' on the Nasdaq National Market.
- 6Stockholders approved an increase in authorized common shares from 500,000,000 to 1,000,000,000.
- 7Approval of new equity incentive plans: the 2003 Omnibus Equity Plan and the Performance Based Management Incentive Plan.